Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05110196
Other study ID # CINC280AIN01
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 3, 2022
Est. completion date June 30, 2025

Study information

Verified date April 2024
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email novartis.email@novartis.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Drugs Controller General of India (DCGI) has granted approval for Rahika® (Capmatinib) film-coated tablet 150 and 200 mg for the treatment of adult patients with advanced/metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping mutation with condition to perform a Phase IV clinical trial in Indian patients. As recommended by DCGI, this Phase IV study has been planned to evaluate the safety and efficacy of capmatinib in treatment of adult Indian patients with advanced/metastatic NSCLC whose tumors have a MET exon 14 skipping mutation positive advanced NSCLC in any line of therapy.


Description:

This is a Phase IV, prospective, multicenter, open-label, interventional study. The study will include approximately 50 patients. The study will include molecular prescreening (28 days for patients who do not have documented MET exon 14 skipping mutation positive results), screening period (28 days), treatment period of 24 weeks, end of treatment (EOT) visit, and follow-up period of 30 days post last dose of study treatment. During the treatment period, study treatment will be administered as capmatinib 400 mg orally as twice daily (BID) on a continuous dosing schedule for 24 weeks. The treatment with capmatinib will be started only when the previous anti-cancer treatment was stopped within 4 weeks or ≥5 x half-life (whichever is longer) in subject who were on prior line/s of treatment. The treatment period begins on Day 1 of Cycle 1. Each treatment cycle will be of 21 days. Cycle 2 will start on Day 22 of the study and will be considered as Cycle 2 Day 22 (C2D22) and so on if there is no temporary discontinuation Patients may be discontinued from treatment earlier due to unacceptable toxicity, disease progression, withdrawal of consent, or at the discretion of the investigator or the patient. These patients will have end of study (EOS) assessment 30 days after the administration of last dose of the study treatment. Every effort will be made by Novartis to continue provision of study treatment capmatinib via post trial access (PTA) to the patients who are ongoing on treatment at the end of the planned duration of study and deriving clinical benefit. Patients transitioning to PTA will also have to compete the EOS Visit assessment after the last dose administration of capmatinib for the current study.


Read more »

Study Design


Intervention

Drug:
Capmatinib 150 mg
Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
Capmatinib 200 mg
Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

See more »

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants with Adverse Events (AEs) Percentage of participants with Adverse Events (AEs), including SAEs, changes in laboratory values, vital signs and ECGs From first dose of study treatment administration until end of study, assessed up to 7 months
Primary Percentage of participants with dose modifications Percentage of participants with dose modifications, including dose interruptions and dose reductions From first dose of study treatment administration until end of treatment, assessed up to 6 months
Primary Dose intensity Dose intensity is defined as the ratio of total dose received and actual duration From first dose of study treatment administration until end of treatment, assessed up to 6 months
Secondary Overall Response Rate (ORR) ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per RECIST 1.1 and by investigator assessment From first dose of study treatment up to a maximum duration of 7 months
Secondary Overall Intracranial Response Rate (OIRR) OIRR is calculated as the ORR (CR+PR) of lesions in the brain for patients who had measureable disease in the brain at baseline From first dose of study treatment up to a maximum duration of 7 months
Secondary Duration of Response (DOR DOR is defined as the time from first documented response of CR or PR to date of first documented progression or death, whichever comes first, as per RECIST 1.1 criteria and by investigator assessment From first documented response to first documented progression or death, assessed up to 7 months
Secondary Time To response (TTR) TTR is defined as duration of time between the date of first dose of capmatinib and the date of first documented response of either CR or PR as per RECIST 1.1 criteria and by investigator assessment From first dose of study treatment up to first documented response, assessed up to 7 months
Secondary Disease Control Rate (DCR) DCR is defined as the proportion of patients with CR or PR or subjects with stable disease per investigator according to RECIST 1.1 criteria and by investigator assessment From first dose of study treatment up to a maximum duration of 7 months
Secondary Progression Free Survival (PFS) PFS is defined as the time from first dose of capmatinib to the date of the first documented radiological progression as per RECIST 1.1 response criteria or death due to any cause From first dose of study treatment to first documented progression or death, assessed up to a maximum duration of 7 months
See also
  Status Clinical Trial Phase
Completed NCT02795156 - Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Phase 2
Terminated NCT02556593 - IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases Phase 2
Active, not recruiting NCT03678350 - Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery Phase 1
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT02273271 - Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo N/A
Withdrawn NCT03408561 - Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer N/A
Active, not recruiting NCT04984811 - NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Phase 2
Completed NCT02922777 - Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. Phase 1
Active, not recruiting NCT01279408 - Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)
Completed NCT00081315 - Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT03731585 - Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment N/A
Active, not recruiting NCT02009449 - A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Phase 1
Completed NCT00540514 - Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer Phase 3
Completed NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Completed NCT02848872 - Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer
Not yet recruiting NCT06222489 - Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT Phase 2
Active, not recruiting NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Phase 1
Terminated NCT01288430 - A Study of DS-2248 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05642195 - Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT02394548 - Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer N/A